Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun, Lin Shen, Manish A. Shah, +22

The Lancet

Chemotherapy Versus ChemotherapyOncologyEsophageal CancerGastrointestinal OncologyClinical Trials +6

3D printing of conducting polymers

Hyunwoo Yuk, Baoyang Lu, Lin Shen, +4

Nature Communications

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Feng‐Hua Wang, Lin Shen, Jin Li, +19

Cancer Communications

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, +16

Nature

Gastrointestinal OncologyMedicineHer2 BlockadeImmunologyGastroenterology +7

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Jing Huang, Jianming Xu, Yun Chen, +44

The Lancet Oncology

Esophageal CancerGastrointestinal OncologyMedicineClinical TrialsPathology +8

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Changsong Qi, Jifang Gong, Jian Li, +23

Nature Medicine

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zixian Wang, Chengxu Cui, Jun Yao, +78

Cancer Cell

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang, +22

Annals of Oncology

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Zhihao Lü, Junye Wang, Yongqian Shu, +27

BMJ

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler, +26

Nature